Bioasis Technologies Inc

Add to watchlist
€0.224
Last updated:06/10/2021
107: F
Bioasis Technologies Inc

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across th… Show more

P/E ratio
28.00x
vs. 0.00x forward

Price is 28.00x times more than EPS €0.008 which eaquals €0.224

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-2.990781M
-5.307938M
-77.48%
-3.473414M
+34.56%
-4.05642M
-16.78%
Cashflow
Sum up money going in and out company
-1.244213M
-3.673138M
-195.22%
-3.229675M
+12.07%
-3.298652M
-2.14%
Total liabilities
All combined debts and obligations
747.523K
787.661K
+5.37%
2.289902M
+190.72%
3.428072M
+49.70%
Company profile
CEO
Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE
Market capitalization
Nano (19.59M)